Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice

Vaccine

Volumn 21, Issue 25-26, 2003, Pages 3885-3900

  Bertolotti Ciarlet, Andrea ^a,c   Ciarlet, Max ^a,d   Crawford, Sue E ^a   Conner, Margaret E ^a,b   Estes, Mary K ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Immunogenicity; Protective efficacy; Rotavirus vaccine; Virus like particles

Indexed keywords

CHOLERA TOXIN; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; QS 21; ROTAVIRUS VACCINE; VIRUS PROTEIN;

ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; DRUG EFFICACY; EXPRESSION VECTOR; FEMALE; IMMUNOGENICITY; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SIMIAN VIRUS; VACCINATION; VIRUS GENE; VIRUS INFECTION; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS STRAIN;

EID: 0242349122     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00308-6     Document Type: Article

References (56)

1. Estes MK. Rotaviruses and their replication. In: Knipe DM, Howley, PM, et al., editors. Fields virology, 4th ed. Philadelphia: Lippincott-Raven Publishers; 2001. p. 1747-85.
2. Kapikian A.Z. A rotavirus vaccine for prevention of severe diarrhoea of infants and young children: development, utilization and withdrawal. Novartis Found. Symp. 238:2001;153-179.
3. Parashar U., Holman R., Cummings K., Staggs N., Curns A., Zimmerman C.et al. Trends in intussusception-associated hospitalizations and deaths among US infants. Pediatrics. 106:2000;1413-1421.
4. Clark H.F., Offit P.A., Ellis R., Krah D., Shaw A.R., Eiden J.J.et al. WC3 reassortant vaccines in children. Arch Virol (Suppl). 12:1996;187-198.
5. Vesikari T. Trials of oral bovine and rhesus rotavirus vaccines in Finland: a historical account and present status. Arch Virol (Suppl). 12:1996;177-186.
6. Murphy T, Gargiullo P, Massoudi M, Nelson D, Jumaan A, Okoro C, et al. The rotavirus intussusception investigation team. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001;344:564-72.
7. Ciarlet M., Estes M.K. Rotavirus and calicivirus infections of the gastrointestinal tract. Curr Opin Gastroenterol. 17:2001;10-16.
8. Choi A.H., Basu M., McNeal M.M., Clements J.D., Ward R.L. Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein. J Virol. 73:1999;7574-7581.
9. Choi A.H., Basu M., McNeal M.M., Flint J., VanCott J.L., Clements J.D.et al. Functional mapping of protective domains and epitopes in the rotavirus VP6 protein. J Virol. 74:2000;11574-11580.
10. Burns J., Siadat-Pajouh M., Krishnaney A., Greenberg H.B. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science. 272:1996;104-107.
11. Herrmann J.E., Chen S., Fynan E., Santoro J., Greenberg H.B., Wang S.et al. Protection against rotavirus infections by DNA vaccination. J Infect Dis. 174(Suppl 1):1996;S93-97.
12. Chen S.C., Fynan E.F., Robinson H.L., Lu S., Greenberg H.B., Santoro J.C.et al. Protective immunity induced by rotavirus DNA vaccines. Vaccine. 15:1997;899-902.
13. Crawford S.E., Labbé M., Cohen J., Burroghs M.H., Zhou Y.J., Estes M.K. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol. 68:1994;5945-5952.
14. Labbé M., Charpilienne A., Crawford S.E., Estes M.K., Cohen J. Expression of rotavirus VP2 produces empty corelike particles. J Virol. 65:1991;2946-2952.
15. Coste A., Sirard J., Johansen K., Chen J., Kraehenbuhl J.P. Nasal immunization of mice with virus-like particles protects offspring against rotavirus diarrhea. J Virol. 74:2000;8966-8971.
16. Crawford S.E., Estes M.K., Ciarlet M., Barone C., O'Neal C., Cohen J.et al. Heterotypic protection and induction of a broad heterotypic neutralization responses by rotavirus-like particles. J Virol. 73:1999;4813-4822.
17. Jiang B., Barniak V., Barone C., O'Neal C., Smith R., Madore H.P.et al. Rotavirus G1 VLPs induce heterotypic protection in a murine model. Vaccine. 17:1999;1005-1013.
18. Madore H.P., Estes M.K., Zarley C., Hu B., Parsons S., Digravio D.et al. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. Vaccine. 17:1999;2461-2471.
19. O'Neal C., Crawford S.E., Estes M.K., Conner M.E. Rotavirus VLPs administered mucosally induce protective immunity. J Virol. 71:1997;8707-8717.
20. O'Neal C., Clements J., Estes M.K., Conner M.E. Rotavirus 2/6-VLPs administered intranasally with cholera toxin, E. coli heat labile toxin and LT-R192G induce protection from rotavirus challenge. J Virol. 72:1998;3390-3393.
21. Ciarlet M., Crawford S.E., Barone C., Bertolotti-Ciarlet A., Ramig R.F., Estes M.K.et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol. 72:1998;9233-9246.
22. Fernández F.M., Conner M.E., Parwani A., Todhunter D., Smith K.L., Crawford S.E.et al. Isotype-specific antibody responses to rotavirus and virus proteins in cows inoculated with subunit vaccines composed of recombinant SA11 rotavirus core-like particles (CLP) or virus-like particles (VLP). Vaccine. 14:1996;1303-1312.
23. Fernández F.M., Conner M.E., Hodgins D.C., Parwani A., Nielsen P., Crawford S.E.et al. Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from cows immunized with recombinant SA11 rotavirus core-like particle (CLP) or virus-like particle (VLP) vaccines. Vaccine. 16:1998;507-516.
24. Kim Y., Nielsen P., Hodgins D., Chang K., Saif L.J. Lactogenic antibody responses in cows vaccinated with recombinant bovine rotavirus-like particles (VLPs) of two serotypes or inactivated bovine rotavirus vaccines. Vaccine. 20:2002;1248-1258.
25. Iosef C., Van Nguyen T., Jeong K., Bengtsson K., Morein B., Kim Y.et al. Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes. Vaccine. 20:2002;1741-1753.
26. Yuan L., Geyer A., Hodgins D., Fan Z., Qian Y., Chang K.et al. Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J Virol. 74:2000;8843-8853.
27. Yuan L., Iosef C., Azevedo M., Kim Y., Qian Y., Geyer A.et al. Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs. J Virol. 75:2001;9229-9238.
28. Belyaev A., Roy P. Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells. Nucleic Acids Res. 21:1993;1219-1223.
29. Malherbe H.H., Strickland-Cholmley M. Simian virus SA11 and the related O agent. Arch Gesamte Virosforsch. 22:1967;235-245.
30. Burns J.W., Chen D., Estes M.K., Ramig R.F. Biological and immunological characterization of a simian rotavirus SA11 variant with an altered genome segment 4. Virology. 169:1989;427-435.
31. Estes M.K., Graham D.Y., Ramig R.F., Ericson B.L. Heterogeneity in the structural glycoprotein (VP7) of simian rotavirus SA11. Virology. 122:1982;8-14.
32. Franco M., Greenberg H.B. Immunity to rotavirus in T-cell-deficient mice. Virology. 338:1997;169-179.
33. Ciarlet M., Estes M.K., Barone C., Ramig R.F., Conner M.E. Analysis of host range restriction determinants in the rabbit model: comparison of homologous and heterologous rotavirus infections. J Virol. 72:1998;2341-2351.
34. Ciarlet M., Estes M.K., Conner M.E. Simian rhesus rotavirus is a unique heterologous (non-lapine) rotavirus strains capable of productive replication and horizontal transmission in rabbits. J Gen Virol. 81:2000;1237-1249.
35. Ciarlet M, Conner ME. Evaluation of rotavirus vaccines in small animal models. In: Gray JJ, Desselberger U, editors. Methods in molecular medicine. Rotaviruses: methods and protocols, vol. 34. Totowa, NJ: Humana Press; 2000. p. 147-87.
36. Estes M.K., Crawford S.E., Peñaranda M.E., Petrie B.L., Burns J.W., Chan W.et al. Synthesis and immunogenicity of the rotavirus major capsid antigen using a baculovirus expression system. J Virol. 61:1987;1488-1494.
37. Estes M.K., Mason B., Crawford S.E., Cohen J. Cloning and nucleotide sequence of the simian rotavirus gene 6 that codes for the major inner capsid protein. Nucleic Acids Res. 12:1984;1875-1887.
38. Kensil CR, Wan JY, Soltysik S. Structural and immunological characterization of the vaccine adjuvant QS-21. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press; 1995. p. 525-41.
39. Ernst H., Duhl J.A. Nucleotide sequence of genomic segment 2 of the human rotavirus Wa. Nucleic Acids Res. 17:1989;4382.
40. Ito H., Sugiyama M., Masubuchi K., Mori Y., Minamoto N. Complete nucleotide sequence of a group A avian rotavirus genome and a comparison with its counterparts of mammalian rotaviruses. Virus Res. 75:2001;123-138.
41. Kumar A., Charpilienne A., Cohen J. Nucleotide sequence of the gene encoding for the RNA binding protein (VP2) of RF bovine rotavirus. Nucleic Acids Res. 17:1989;2126.
42. Mitchell D.B., Both G.W. Completion of the genomic sequence of the simian rotavirus SA11: nucleotide sequences of segments 1, 2, and 3. Virology. 177:1990;324-331.
43. Tian Y., Tarlow O., McCrae M.A. Nucleotide sequence of gene 2 of the UK tissue culture adapted strain of bovine rotavirus. Nucleic Acids Res. 8:1990;4015.
44. Charpilienne A., Lepault J., Rey F., Cohen J. Identification of rotavirus VP6 residues located at the interface with VP2 that are essential for capsid assembly and transcriptase activity. J Virol. 76:2002;7822-7831.
45. McNeal M.M., Rae M., Bean J., Ward R.L. Antibody-dependent and -independent protection following intranasal immunization of mice with rotavirus particles. J Virol. 73:1999;7565-7573.
46. French T.J., Roy P. Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV. J Virol. 64:1990;1530-1536.
47. French T.J., Marshall J., Roy P. Assembly of double-shelled, viruslike particles of bluetongue virus by simultaneous expression of four structural proteins. J Virol. 64:1990;5695-5700.
48. González S., Affranchino J. Assembly of double-layered virus-like particles in mammalian cells by coexpression of human rotavirus VP2 and VP6. J Gen Virol. 76:1995;2357-2360.
49. McNeal M.M., Rae M., Conner M.E., Ward R.L. Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21. Virology. 243:1998;158-166.
50. O'Neal C., Harriman G., Conner M.E. Protection of the villus epithelial cells of the small intestine from rotavirus infection does not require immunoglobulin A. J Virol. 74:2000;4102-4109.
51. McNeal M.M., VanCott J.L., Choi A.H.C., Basu M., Flint J.A., Stone S.et al. CD4+ T cells are the only lymphocytes need to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192R). J Virol. 76:2002;560-568.
52. Bishop R.F., Barnes G., Cipriani E., Lund J. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med. 309:1983;72-76.
53. Jain V., Parashar U.D., Glass R.I., Bhan M.K. Epidemiology of rotavirus in India. Indian J Pediatr. 68:2001;855-862.
54. Velázquez F., Matson D., Calva J., Guerrero L., Morrow A., Carter-Campbell S.et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med. 335:1996;1022-1028.
55. Ciarlet M., Hoshino Y., Liprandi F. Single point mutations may affect the serotype reactivity of serotype G11 rotavirus strains: a widening spectrum? J Virol. 71:1997;8213-8220.
56. Esquivel F.R., López S., Guitierrez X., Arias C.F. The internal rotavirus protein VP6 primes for an enhanced neutralizing antibody response. Arch Virol. 145:2000;813-825.